Elbit’s investments in the bio-tech and medical devices fields, mainly in the image guided treatment business, clinical trials, gene therapy, genomics and drug delivery fields are preformed through our subsidiaries, InSightec Ltd. and Gamida Cell Ltd. Such investments along with the development and operation of our Chain of Multi-Specialty Tertiary Hospitals in India will enable a close collaboration and an added value in this field.
Our subsidiary, InSightec Ltd. (in which we hold approximately 52%), is a market-oriented, technology-based company, committed to improve efficacy and quality of healthcare delivery. Its objectives are to become the market leader in Image Guided High Intensity Focused Ultrasound (FUS), achieving a significant improvement in the quality and efficiency of the treatment while demonstrating cost effectiveness. Among InSightec’s shareholders are also GE Equity Capital, a subsidiary of General Electric Company (NYSE: GE) and MediTech Advisors LP.
For additional information please see InSightec’s web site: http://www.insightec.com
Through our wholly owned subsidiary, Elscint Ltd., our Company invests in Gamida Cell Ltd. (in which our it indirectly holds approximately 27.49%) and is currently its largest shareholder. Gamida Cell, is a developer of a pipeline of cell therapeutics to fill the unmet clinical need for products with an ample supply of stem cells, to effectively treat debilitating and often fatal illnesses such as cancer, cardiovascular disease and neurological disorders.
For additional information please see Gamida Cell’s web site: http://www.gamida-cell.com/